Literature DB >> 19455564

Transient expression of genes delivered to newborn rat liver using recombinant adeno-associated virus 2/8 vectors.

Maude Flageul1, Dominique Aubert, Virginie Pichard, Tuan Huy Nguyen, Ali Nowrouzi, Manfred Schmidt, Nicolas Ferry.   

Abstract

BACKGROUND: In vivo adeno-associated virus (AAV) delivery to adult liver results in sustained expression of the transgene. However, it has been suggested that AAV delivery to the newborn liver may result in transient expression. In the present study, we analysed transgene expression after AAV8 delivery of a therapeutic or a marker gene to newborn rat liver.
METHODS: Recombinant AAV 8 vectors carrying either the human UGT1A1 cDNA or the lacZ gene were injected intravenously in 2-day-old Gunn or Wistar rats. Serum bilirubin level was recorded in Gunn rats and beta-galactosidase expression was monitored by immunohistochemistry or enzyme activity. The molecular forms of AAV genome were analysed by the polymerase chain reaction and Southern blotting in whole liver and by the quantitative polymerase chain reaction in macroscopically dissected beta-galactosidase clusters.
RESULTS: In Gunn rat, complete serum bilirubin normalization occurred after AAV delivery but hyperbilirubinemia resumed thereafter. Similarly, beta-galactosidase expression was maximum at day 7, but only a few (less than 1%) beta-galactosidase positive cells were recorded at 1 or 3 months. These cells gathered in small clusters and the AAV copy number was 75-fold higher in positive cell clusters than in the surrounding parenchyma.
CONCLUSIONS: The results obtained in the present study show that in vivo AAV delivery to newborn rats results in transient expression in most hepatocytes. Expression of the trangene was persistent in small clusters of cells and preliminary data support the hypothesis that integration of the viral genome occurs in these clusters. Altogether, our data confirm the low efficiency of AAV vectors for gene therapy of liver diseases when delivered in the newborn period.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455564     DOI: 10.1002/jgm.1343

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  14 in total

1.  Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver.

Authors:  Ali Nowrouzi; Magalie Penaud-Budloo; Christine Kaeppel; Uwe Appelt; Caroline Le Guiner; Philippe Moullier; Christof von Kalle; Richard O Snyder; Manfred Schmidt
Journal:  Mol Ther       Date:  2012-03-27       Impact factor: 11.454

2.  Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I.

Authors:  L Bočkor; G Bortolussi; A Iaconcig; G Chiaruttini; C Tiribelli; M Giacca; F Benvenuti; L Zentilin; A F Muro
Journal:  Gene Ther       Date:  2017-08-14       Impact factor: 5.250

3.  Efficient gene transfer into the mouse lung by fetal intratracheal injection of rAAV2/6.2.

Authors:  Marianne Carlon; Jaan Toelen; Anke Van der Perren; Luk H Vandenberghe; Veerle Reumers; Lourenço Sbragia; Rik Gijsbers; Veerle Baekelandt; Uwe Himmelreich; James M Wilson; Jan Deprest; Zeger Debyser
Journal:  Mol Ther       Date:  2010-07-27       Impact factor: 11.454

4.  Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways.

Authors:  Marianne S Carlon; Dragana Vidović; James Dooley; Marina Mori da Cunha; Michael Maris; Youlia Lampi; Jaan Toelen; Chris Van den Haute; Veerle Baekelandt; Jan Deprest; Erik Verbeken; Adrian Liston; Rik Gijsbers; Zeger Debyser
Journal:  Hum Gene Ther       Date:  2014-03-26       Impact factor: 5.695

5.  Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer.

Authors:  Gabriella Cotugno; Patrizia Annunziata; Alessandra Tessitore; Thomas O'Malley; Anita Capalbo; Armida Faella; Rosa Bartolomeo; Patricia O'Donnell; Ping Wang; Fabio Russo; Meg M Sleeper; Van W Knox; Steven Fernandez; Leah Levanduski; John Hopwood; Elvira De Leonibus; Mark Haskins; Alberto Auricchio
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

6.  Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transduction.

Authors:  Gabriella Cotugno; Patrizia Annunziata; Maria Vittoria Barone; Marianthi Karali; Sandro Banfi; Alberto Auricchio
Journal:  PLoS One       Date:  2012-03-13       Impact factor: 3.240

Review 7.  Perinatal gene transfer to the liver.

Authors:  Tristan R McKay; Ahad A Rahim; Suzanne M K Buckley; Natalie J Ward; Jerry K Y Chan; Steven J Howe; Simon N Waddington
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

8.  Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer.

Authors:  Giulia Bortolussi; Lorena Zentilin; Gabriele Baj; Pablo Giraudi; Cristina Bellarosa; Mauro Giacca; Claudio Tiribelli; Andrés F Muro
Journal:  FASEB J       Date:  2011-11-17       Impact factor: 5.191

9.  Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins.

Authors:  Jasmina Lovric; Miguel Mano; Lorena Zentilin; Ana Eulalio; Serena Zacchigna; Mauro Giacca
Journal:  Mol Ther       Date:  2012-07-31       Impact factor: 11.454

10.  Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver.

Authors:  Bryan A Piras; Daniel M O'Connor; Brent A French
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.